Proactive Investors - Run By Investors For Investors

AusCann Group appoints PCI Pharma to manufacture first product line

The company's first product line is medicinal cannabis hard shell capsules.
cannabis leaf and green tablets
The proprietary solid hard shell capsules are for the treatment of chronic pain

AusCann Group Holdings Ltd (ASX:AC8) has achieved another milestone after appointing TGA-licensed PCI Pharma to manufacture and release its first medicinal cannabis product line.

The proprietary solid hard shell capsules for the treatment of chronic pain are scheduled for release in the first half of 2019.

The capsules will initially target a market that is estimated to be 1.9 million Australians who suffer chronic neuropathic pain.

Sufferers can access the treatment through the TGA’s special access scheme (SAS).

READ: AusCann Group releases education resources for medical cannabis awareness

AusCann’s managing director Elaine Darby said: “AusCann elected to work with PCI Pharma due to their significant experience in providing manufacturing services of solid dose potent products to high standards of safety and quality.

“This allows AusCann to bring its first hard shell capsules into the chronic pain market as quickly as possible, while continuing to focus on the development of our second generation cannabinoid pharmaceutical products.”

Western Australia site proposed in early 2019

The manufacturing work by PCI Pharma complements AusCann’s research and development site it proposes to establish in Western Australia in early 2019.

The site will be focused on the development of AusCann’s cannabinoid pharmaceutical product pipeline.

It will encompass cultivation, extraction, new product development and manufacturing activities.

3.2 million Australians suffer chronic pain

Around 3.2 million Australians suffer chronic pain and existing treatments are lacking in efficacy and have notable side effects.

The main reason for the use of medicinal cannabis global is for the treatment of chronic pain.

Notably, it is also an area where there is clinical data supporting its use.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
muffins and cannabis
November 30 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
medical cannabis concept
February 11 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use